Press release
Prurigo Nodularis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho
Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 5+ key pharma and biotech companies are working on 5+ pipeline drugs in the Prurigo Nodularis therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years."Prurigo Nodularis Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Prurigo Nodularis Therapeutics Market.
The report provides a detailed description of the Prurigo Nodularis drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any).
The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.
Get a Detailed Overview of the Prurigo Nodularis Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/prurigo-nodularis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Prurigo Nodularis Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Prurigo Nodularis therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Prurigo Nodularis treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Prurigo Nodularis drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Prurigo Nodularis treatment market.
Learn More about the Clinical and Commercial Development Activities in the Prurigo Nodularis Therapeutics Domain:
https://www.delveinsight.com/report-store/prurigo-nodularis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
The Report Covers the Emerging Prurigo Nodularis Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
Route of Administration
Prurigo Nodularis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravenous
• Oral
• Parenteral
• Subcutaneous
• Topical
Molecule Type
Products have been categorized under various Molecule types such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
Request for Sample PDF to Understand More About the Prurigo Nodularis Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Prurigo Nodularis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Prurigo Nodularis. Currently, Chugai/Galderma are leading the therapeutics market with thei Prurigo Nodularis drug candidates in the most advanced stage of clinical development.
Prurigo Nodularis Companies in the Therapeutics Market Include:
• Menlo Therapeutics
• Galderma R&D
• Kiniksa Pharmaceuticals
• Sanofi
• Maruho
And Many Others
Emerging and Marketed Prurigo Nodularis Therapies Covered in the Report Include:
• Nemolizumab: Chugai/Galderma
• Nalbuphine ER: Trevi Therapeutics
• Vixarelimab: Kiniksa Pharmaceuticals
And Many More
Get an in-depth Assessment of the Emerging Therapies and Prurigo Nodularis Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Prurigo Nodularis Current Treatment Patterns
4. Prurigo Nodularis - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Prurigo Nodularis Late-Stage Products (Phase-III)
7. Prurigo Nodularis Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Prurigo Nodularis Discontinued Products
13. Prurigo Nodularis Product Profiles
14. Prurigo Nodularis Companies
15. Prurigo Nodularis Drugs
16. Dormant and Discontinued Products
17. Prurigo Nodularis Unmet Needs
18. Prurigo Nodularis Future Perspectives
19. Prurigo Nodularis Analyst Review
20. Appendix
21. Report Methodology
Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/prurigo-nodularis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr
Other Trending Healthcare Reports by DelveInsight
• Radiofrequency Ablation Devices Market
https://www.delveinsight.com/report-store/radiofrequency-ablation-devices-market
• Smart Inhalers Market
https://www.delveinsight.com/report-store/smart-inhalers-market
• Persistent Depressive Disorder Market
https://www.delveinsight.com/report-store/persistent-depressive-disorder-market
• Dysthymia Market
https://www.delveinsight.com/report-store/dysthymia-market
• Nasopharyngeal Carcinoma Market
https://www.delveinsight.com/report-store/nasopharyngeal-carcinoma-market
• Spinal Fusion Devices Market
https://www.delveinsight.com/report-store/spinal-fusion-devices-market
• Stereotactic Surgery Devices Market
https://www.delveinsight.com/report-store/stereotactic-surgery-devices-market
• Structural Heart Devices Global Market
https://www.delveinsight.com/report-store/structural-heart-devices-market-market
• Intracardiac Echocardiography Devices Market
https://www.delveinsight.com/report-store/intracardiac-echocardiography-devices-market
• Cardiac Monitoring System Market
https://www.delveinsight.com/report-store/cardiac-monitoring-system-market
• Desmoplastic Small Round Cell Tumors (dsrcts) Market
https://www.delveinsight.com/report-store/desmoplastic-small-round-cell-tumors-market
• Artificial Cornea and Corneal Implant Market
https://www.delveinsight.com/report-store/artificial-cornea-and-corneal-implant-market
• Deep Brain Stimulation Devices Market
https://www.delveinsight.com/report-store/deep-brain-stimulation-devices-market
• Obesity Market
https://www.delveinsight.com/report-store/weight-loss-weight-management-obesity-market
• Messenger RNA (mRNA)-based Vaccines and Therapeutics Market
https://www.delveinsight.com/report-store/global-messenger-rna-mrna-based-vaccines-and-therapeutics-market
• Narcolepsy Market
https://www.delveinsight.com/report-store/narcolepsy-market
Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com
428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Prurigo Nodularis Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Menlo Therapeutics, Galderma R&D, Kiniksa Pharmaceuticals, Sanofi, Maruho here
News-ID: 3117242 • Views: …
More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead…

Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore…

Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight…

Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market…
More Releases for Prurigo
Prurigo Nodularis Treatment Market Forecast 2025-2034: Comprehensive Analysis An …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Projected Growth of the Prurigo Nodularis Treatment Market?
In recent times, the prurigo nodularis treatment market has seen robust growth. The market value is projected to expand from $1.64 billion in 2024 to $1.73 billion in 2025, representing a compound annual growth rate (CAGR) of 5.4%. The notable growth in the…
Prurigo Nodularis Treatment Market Opportunities & Challenges, Novel Therapies T …
The Global Prurigo Nodularis Treatment Market reached USD 964.3 million in 2022 and is projected to witness lucrative growth by reaching up to USD 1.1 billion by 2031. The Global Prurigo Nodularis Treatment Market is exhibiting at a CAGR of 3.7% during the forecast period 2024-2031.
Prurigo Nodularis Treatment Market report, published by DataM Intelligence, provides in-depth insights and analysis on key market trends, growth opportunities, and emerging challenges. Committed to…
Prurigo Nodularis Pipeline: Emerging Therapies Set to Reshape the Prurigo Nodula …
The treatment landscape of Prurigo Nodularis (PN), a chronic, intensely pruritic skin disorder, is undergoing a dynamic transformation, fueled by a growing pipeline of novel therapeutics from leading pharma and biotech companies. Notable players such as Menlo Therapeutics, Galderma R&D, and Kiniksa Pharmaceuticals are driving innovation with therapies targeting underlying immune dysregulation, including IL-31 and JAK/STAT pathways, central to PN pathogenesis. These emerging drugs aim to address the high unmet…
Prurigo Nodularis Treatment Market Current Status and Future Prospects till 2031
Prurigo Nodularis (PN) is a chronic dermatologic condition marked by intense itching and the development of nodules on the skin. The Prurigo Nodularis Treatment Market focuses on therapeutic interventions to alleviate symptoms and provide relief to patients suffering from this condition. Treatments include topical corticosteroids, immunosuppressants, and biologic therapies. The current market value of Prurigo Nodularis treatment is driven by the increasing awareness of PN and advancements in treatment options.…
Prurigo Nodularis Treatment Market Size, Share | Forecast 2032
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Prurigo Nodularis Treatment Market size is growing at a moderate pace with substantial growth rates over the last few years and is estimated that the market will grow significantly in the forecasted period i.e. 2021 to 2028.
Market Overview for Prurigo Nodularis Treatment Market
Prurigo Nodularis Treatment Market OverviewPrurigo nodularis (PN) is a chronic skin condition characterized by intensely itchy nodules or papules that can significantly impair quality of…
Prurigo nodularis Market: F: Information, Figures and Analytical Insights 2021-2 …
The Prurigo nodularis Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides an in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. We analyzed the…